BostonGene has raised a total of $386 million in funding across two rounds: a $150 million Series A in August 2020, led by SoftBank Vision Fund 2, and a $200 million Series B in November 2024, led by Eldridge and Tiger Global Management. Founded in 2015 and headquartered in Waltham, Massachusetts, BostonGene develops an AI-powered molecular and immune profiling platform that transforms cancer diagnostics and treatment. With a valuation of $1 billion (as of April 2022), the company continues to advance precision oncology through genomics, analytics, and artificial intelligence.